KTTA

+ Watchlist + Portfolio

Pasithea Therapeutics Corp.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.49
52-Week Range: $0.28 – $2.06
Market Cap: $15.91M
P/E (TTM): —
EPS (TTM): -1.59
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.32
PEG Ratio: —
Return on Equity: -65.49%
Return on Assets: -36.00%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 26.25
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-12.17M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-29.76M

KTTA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$113.19K	—	—	—
Gross Profit	$373.36K	—	—	—
Research & Development	$2.67M	$8.10M	$7.20M	$7.98M
Selling, General & Admin	$9.92M	$7.88M	$7.05M	$12.88M
Operating Expenses	$12.59M	$15.98M	$14.25M	$20.86M
Operating Income	-$12.59M	-$15.98M	-$14.25M	-$20.86M
EBITDA	-$12.58M	-$15.33M	-$13.60M	-$20.19M
Pretax Income	-$11.73M	-$15.51M	-$13.90M	-$20.43M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$13.94M	-$15.96M	-$13.90M	-$20.43M
Diluted EPS	-11.03	-13.01	-12.69	-2.91
Diluted Shares	1.26M	1.23M	1.10M	7.03M

KTTA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$33.09M	$16.33M	$6.92M	$55.16M
Receivables	$0.00	$40.50K	$0.00	—
Current Assets	$34.08M	$16.69M	$7.37M	$56.46M
Total Assets	$45.18M	$26.12M	$16.06M	$60.24M
Current Liabilities	$1.88M	$2.63M	$1.12M	$4.97M
Total Debt	$504.38K	$81.68K	$0.00	—
Total Liabilities	$2.68M	$2.72M	$1.28M	$5.02M
Retained Earnings	-$19.36M	-$35.32M	-$49.58M	-$70.01M
Shareholders' Equity	$42.50M	$23.40M	$14.78M	$55.22M
Working Capital	$32.20M	$14.06M	$6.25M	$51.49M

KTTA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.69M	-$13.43M	-$13.92M	-$15.21M
Capital Expenditure	-$107.10K	-$34.30K	—	—
Free Cash Flow	-$13.80M	-$13.46M	-$13.92M	-$15.21M
Depreciation & Amortisation	$5.09K	$648.45K	$649.03K	$662.59K
Stock-Based Compensation	$835.06K	$592.27K	$773.69K	$297.47K
Investing Cash Flow	-$2.93M	$399.01K	$0.00	$11.00K
Financing Cash Flow	-$3.21M	-$3.73M	$4.52M	$63.52M
Share Repurchases	-$3.21M	-$3.73M	$0.00	—
Net Change in Cash	-$19.82M	-$16.75M	-$9.41M	$48.32M

KTTA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.73M	$2.15M	$1.36M	$2.74M	$2.94M	$3.69M
Selling, General & Admin	$1.95M	$1.66M	$1.75M	$7.51M	$1.93M	$2.03M
Operating Expenses	$3.68M	$3.81M	$3.11M	$10.26M	$4.88M	$5.71M
Operating Income	-$3.68M	-$3.81M	-$3.11M	-$10.26M	-$4.88M	-$5.71M
EBITDA	-$3.52M	-$3.65M	-$2.93M	-$10.10M	-$4.72M	-$5.56M
Pretax Income	-$3.56M	-$3.72M	-$3.04M	-$10.11M	-$2.87M	-$5.27M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$3.56M	-$3.72M	-$3.04M	-$10.11M	-$2.87M	-$5.27M
Diluted EPS	-1.61	-0.66	-0.41	—	-0.12	-0.16
Diluted Shares	2.21M	5.64M	7.44M	—	24.34M	32.10M

KTTA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.34M	$7.22M	$4.12M	$55.16M	$50.40M	$45.66M
Current Assets	$6.12M	$8.64M	$5.53M	$56.46M	$52.73M	$48.24M
Total Assets	$14.66M	$17.01M	$13.63M	$60.24M	$56.35M	$51.71M
Current Liabilities	$1.59M	$1.74M	$1.38M	$4.97M	$1.49M	$1.84M
Total Liabilities	$1.68M	$1.83M	$1.42M	$5.02M	$1.54M	$1.87M
Retained Earnings	-$53.15M	-$56.86M	-$59.90M	-$70.01M	-$72.88M	-$78.15M
Shareholders' Equity	$12.98M	$15.18M	$12.21M	$55.22M	$54.81M	$49.84M
Working Capital	$4.53M	$6.90M	$4.15M	$51.49M	$51.24M	$46.41M

KTTA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.06M	-$3.87M	-$2.89M	-$5.40M	-$4.79M	-$4.71M
Free Cash Flow	-$3.06M	-$3.87M	-$2.89M	-$5.40M	-$4.79M	-$4.71M
Depreciation & Amortisation	$162.36K	$161.09K	$181.59K	$157.54K	$157.54K	$157.54K
Stock-Based Compensation	$98.56K	$57.65K	$52.99K	$88.28K	$139.18K	$329.94K
Financing Cash Flow	$1.47M	$5.74M	-$116.14K	$56.42M	$750.00	$8.48K
Net Change in Cash	-$1.58M	$1.87M	-$3.01M	$51.04M	-$4.79M	-$4.70M

Market Snapshot

About

Pasithea Therapeutics is a biotechnology company focused on developing treatments for psychiatric and neurological disorders. The company's pipeline includes therapies targeting depression, addiction, pain management, and other central nervous system conditions. Pasithea leverages novel mechanisms of action and drug delivery technologies to address significant unmet medical needs in mental health.